Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

83%

5 of 6 completed trials have results

Key Signals

5 with results

Enrollment Performance

Analytics

Phase 2
4(66.7%)
Phase 1
2(33.3%)
6Total
Phase 2(4)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT01450826Phase 2Completed

Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide

Role: lead

NCT01113398Phase 2Completed

AMG 102 and Avastin for Recurrent Malignant Glioma

Role: lead

NCT01303835Phase 2Completed

Low Dose Naltrexone for Glioma Patients

Role: lead

NCT00979017Phase 2Completed

Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme

Role: lead

NCT00610571Phase 1Completed

Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas

Role: lead

NCT00939991Phase 1Completed

Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas

Role: lead

All 6 trials loaded